Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Top Cited Papers
- 1 August 2015
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 14 (8) , 855-866
Abstract
No abstract availableKeywords
All Related Versions
This publication has 120 references indexed in Scilit:
- Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following EndocytosisPLOS ONE, 2013
- Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s diseaseActa Neuropathologica, 2013
- Direct Observation of the Interconversion of Normal and Toxic Forms of α-SynucleinCell, 2012
- A Novel “Molecular Tweezer” Inhibitor of α-Synuclein Neurotoxicity in Vitro and in VivoNeurotherapeutics, 2012
- An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neuronsBrain Research, 2011
- Pre‐fibrillar α‐synuclein variants with impaired β‐structure increase neurotoxicity in Parkinson's disease modelsThe EMBO Journal, 2009
- Intrabody and Parkinson's diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- α-synuclein locus duplication as a cause of familial Parkinson's diseaseThe Lancet, 2004
- The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementiaAnnals of Neurology, 2003
- NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively UnfoldedBiochemistry, 1996